



Wednesday 3 May (times in PT)	
09:00-09:15	Welcome & Opening Address
09:15-10:00	Opening Keynote Antiviral Drug Development for Respiratory Pathogens <i>Rich Whitley, University of Alabama, Birmingham, AL, USA</i>
10:00-11:30 10:00-10:25 10:25-10:50 10:50-11:15 11:15-11:30	Session 1: Preclinical – Viral Targets Co-Chairs: TBC Insights from Coronavirus Replication in Developing Antivirals <i>Mark Denison, Vanderbilt University Medical Center, Nashville, Tennessee, USA</i> A molecularly engineered lectin for the prevention and treatment of influenza and coronaviruses <i>David Markovitz, University of Michigan, Ann Arbor, MI, USA</i> Non-nucleoside RSV polymerase inhibitor <i>Richard Plemper, Georgia State University, Atlanta, GA, USA</i> Panel Discussion
11:30-11:45	Coffee Break



<p>11:45-13:15</p>	<p>Session 2: Preclinical - Host-Directed Antiviral Therapeutics Co-Chairs: TBC</p>
<p>11:45-12:10</p>	<p>Harnessing Interferon Responses as Potential Broad Spectrum Respiratory Antiviral Treatments <i>Vangelis Andreakos, Biomedical Research Foundation, Academy of Athens, Greece</i></p>
<p>12:10-12:35</p>	<p>Towards a novel host-targeted anti-infective strategy for COVID-19 and other acute respiratory viral diseases <i>Stephan Ludwig, Westfaelische-Wilhelms-University, Muenster, Germany</i></p>
<p>12:35-13:00</p>	<p>Combined Inhibition of Viral and Host Factors to Maximize Antiviral Activity <i>Sara Cherry, University of Pennsylvania, Philadelphia PA, USA</i></p>
<p>13:00-13:15</p>	<p>Panel Discussion</p>
<p>13:15-14:15</p>	<p>Lunch and Poster Viewing</p>
<p>14:15-15:45</p>	<p>Session 3 (Oral Abstract Session 1) - Preclinical Development Co-Chairs: TBC</p> <p>6 x 15 min presentations (12 plus 3 for Q&A)</p>
<p>15:45-16.05</p>	<p>Coffee Break</p>



<p>16:05-18:00</p>	<p>Session 4: Clinical Trial Design Issues/Human Challenge/Omics Co-Chairs: TBC</p>
<p>16:05-16.20</p>	<p>Randomized, Placebo Control Trials including of EUA Drugs <i>Speaker TBC</i></p>
<p>16:20-16.35</p>	<p>RECOVERY Trial <i>Peter Horby, University of Oxford, Oxford, UK</i></p>
<p>16:35-16.50</p>	<p>Human Challenge Model <i>Chris Chiu, Imperial College, London, UK</i></p>
<p>16:50-17.10</p>	<p>Omics in Clinical Trials <i>Teresa Aydillo, Icahn School of Medicine at Mount Sinai, New York, NY, USA</i></p>
<p>17:10-17:25</p>	<p>Fully Remote Trials <i>Caleb Skipper, University of Minnesota, Minneapolis, MN, USA</i></p>
<p>17:25-18.00</p>	<p>Panel Discussion</p>
<p>18:30 – 20.30</p>	<p>Conference Reception – off site (TBC)</p>



Thursday 4 May (times in PT)	
08:30-10:45	Session 5: Updates on Clinical Trials Co-Chairs: TBC
08:30-09:00	Keynote Talk REMAP-CAP: Preparing for the Pandemic and Translating the Network into Seasonal Threats <i>Srinivas Murthy, BC Children's Hospital, Vancouver, Canada</i>
09:00-09:20	Clinical Trials of Severe Viral Pneumonia <i>Bin Cao, China-Japan Friendship Hospital, Beijing, China</i>
09:20-9:40	Monoclonal Antibodies – Current State and Future Directions <i>Speaker TBC</i>
9:40-10:00	Antiviral Therapies for Children <i>Janet Englund, Seattle Children's Hospital, Seattle, WA, USA</i>
10:00-10:20	Small Molecules and Antibodies for RSV <i>Angela Branche, University of Rochester Medical Center, Rochester, NY, USA</i>
10:20-10:45	Panel Discussion
10:45-11:05	Coffee Break
11:05-12:35	Session 6 (Oral Abstract Session 2) – Antivirals, Monoclonal Antibodies and Combinations Co-Chairs: TBC 6 x 15 min presentations (12 plus 3 for Q&A)
12:35-13:35	Lunch and Poster Viewing



13:35-15:30	Session 7 - Clinical Trial and Regulatory Issues Co-Chairs: TBC
13:35-14:05	Keynote Talk: Drug Development, EUAs and The Balance of Preparedness and Data Generation During a Pandemic <i>Rick Bright, Washington, DC, USA</i>
14:05-14:25	Regulatory Framework for Moving from EUA to Licensure and Controlled Trials of EUAd agents <i>Stephanie Troy, US FDA, Silver Spring, MD, USA</i>
14:25-14:45	Clinical Trial Endpoints for Approval of Antiviral Therapeutics <i>Marco Cavaleri, EMEA, Amsterdam, The Netherlands</i>
14:45-15:05	Combination Therapy <i>Mariana Baz, CHU de Québec-Université Laval, Québec, Canada</i>
15:05-15:25	Regulatory Framework for Pan-Viral or Host-Directed Therapy <i>Speaker TBC</i>
15:25-15:40	Panel Discussion
15:40-16:00	Coffee Break
16:00-18:00	Session 8 - Treatment Updates Co-Chairs: TBC
16:00-16:45	State of the Art of COVID-19 Therapy <i>Cameron Wolfe, Duke University Medical Center, NC, USA</i>
16:45-18:00	5 x 15 min presentations (12 plus 3 for Q&A)
18:00-19.30	Poster Reception and Poster viewing



Friday 5 May (times in PT)	
08:30-08:40	Introduction to Roberts/Tisdale Lectureship <i>Maria Zambon, Public Health England, London UK / Chair of ISIRV</i>
08:40-09:25	Keynote Talk – Roberts/Tisdale Lectureship Title TBC <i>Wendy Barclay, Imperial College London, UK</i>
09:25-10:55 09:25-09:50 09:50-10:15 10:15-10:40 10:40-10:55 10:55-11:15	Session 9: The Right Drug for the Right Patient: Optimizing Antiviral Treatment Co-Chairs: TBC Role of Genomic Surveillance in Tracking Emergence of Resistance Over Time <i>Adam Luring, University of Michigan, Ann Arbor, MI, USA</i> Developing Diagnostics to Optimize Antiviral Use <i>Lisa Ng, A* STAR Infectious Diseases Labs, Singapore</i> Role of Misinformation and Erosion of Social Trust in Response to Pandemics <i>Rachel Moran, University of Washington, Seattle, WA, USA</i> Panel Discussion Coffee Break



<p>11:15-12:45</p>	<p>Session 10: (Oral Abstract Session 3) – Surveillance & Antiviral Resistance Co-Chairs: TBC</p> <p>6 x 15 min presentations (12 plus 3 for Q&A)</p>
<p>12:45-13:45</p>	<p>Lunch</p>
<p>13:45-15:15</p> <p>13:45-14:10</p> <p>14:10-14:35</p> <p>14:35-15:00</p> <p>5:00-15:15</p>	<p>Session 11: Access to Care/Global Rollout Co-Chairs: TBC</p> <p>Global Public Health Security and Justice for Vaccines and Therapeutics in the COVID-19 Pandemic <i>Sylvie Briand, WHO, Geneva, Switzerland</i></p> <p>Ensuring equitable access to treatments for disease X <i>Nicole Lurie, CEPI, Washington, DC, USA</i></p> <p>Challenges in global licensure, financing and creation of an international marketplace for therapeutics <i>Speaker TBC</i></p> <p>Panel Discussion</p>
<p>15:15- 15.30</p>	<p>Summary & Close</p>